We speculate that E-CRP could be therapeutically beneficial for infections with antibiotic-resistant pneumococcal strains, such as, strain 106 resistant to clindamycin, strain 109 resistant to clarithromycin, strain 999 resistant to penicillin, and others (72, 73). The gene discussed is RNASE2CP; the disease is infection.